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Background: This study examines the cost-effectiveness of sentinel lymph node biopsy, a potentially less morbid procedure,
compared with inguinofemoral lymphadenectomy (IFL) among women with stage I and stage II vulval squamous cell carcinoma.
Methods: A model-based economic evaluation was undertaken based on clinical evidence from a systematic review of published
sources. A decision tree model was developed with the structure being informed by clinical input, taking the perspective of the
health-care provider.
Results: For overall survival for 2 years, IFL was found to be the most cost-effective option and dominated all other strategies,
being the least costly and most effective. For morbidity-free related outcomes for 2 years, sentinel lymph node (SLN) biopsy with
99mTc and blue dye and haematoxylin & eosin (H&E) histopathology, with ultrastaging and immunohistochemistry reserved for
those that test negative following H&E is likely to be the most effective approach.
Conclusion: SLN biopsy using 99mTc and blue dye with ultrastaging may be considered the most cost-effective strategy based on
the outcome of survival free of morbidity for 2 years. The findings here also indicate that using blue dye and H&E for the
identification of the SLN and the identification of metastasis, respectively, are not sensitive enough to be used on their own.
Vulval cancer represents B3–5% of all gynaecological malignan-
cies and 1% of all female cancers (Hacker, 2005). It is more often
seen in older women, although risk factors such as HPV (Macnab
et al, 1986) and HIV (Elit et al, 2005) mean that it is also seen in
younger women. In 90% of cases, it develops as a squamous cell
carcinoma with the remainder being melanoma, Bartholin’s gland
tumours, adenocarcinoma and basal cell carcinomas.
Current treatment for early squamous cell vulval cancer consists
of radical excision of the tumour with inguinofemoral lymphade-
nectomy (IFL) (van der Zee et al, 2008). This treatment is effective
in terms of averting groin recurrence; however, it would ideally
only be used in women with nodal metastasis. Given that only
25–35% (de Hullu et al, 2000; Hampl et al, 2008) of women with
presumed early-stage vulval cancer have metastasis this means that
for 65–75% of women IFL will have been of no benefit, but patients
will still be at increased risk from the significant morbidity
resulting from the procedure (de Hullu et al, 2002). In the short-
term patients may suffer wound breakdown or infection, while in
the long-term lower limb lymphedema and erysipelas (type of skin
infection) can occur beyond 1 year (van der Zee et al, 2008).
In spite of the morbidity of IFL, it has traditionally been preferred,
as unrecognised disease in the inguinofemoral lymph nodes is
associated with a very high risk of mortality.
An accurate test to identify metastasis in the inguinofemoral
lymph nodes with a high degree of accuracy would mean that only
women with confirmed nodal disease would receive IFL, thus
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sparing many women from the unnecessary morbidity associated
with the procedure.
It has been shown that the various imaging modalities are not
sufficiently sensitive strategies to identify women with groin
metastases (Selman et al, 2005), and therefore pre-operative
imaging of the groin is not a good strategy to identify women
who should undergo IFL. Instead, sentinel lymph node (SLN)
biopsy is used to identify and surgically excise the first draining
lymph node from the primary cancer. The lymph node is then
examined through histopathogical techniques to detect for the
presence of metastasis. Only women that test positive for a
metastasis would then go on to receive an IFL. Sentinel lymph
node biopsy may consist of injection of one or both of blue dye and
99mTc (technetium-99m-labelled nanocolloid). A key advantage of
these biopsy procedures is that they are associated with a much
lower morbidity rate than IFL (van der Zee et al, 2008). However, it
is acknowledged there is a risk that a false-negative SLN biopsy
could result in a woman developing a groin recurrence with the
associated higher risk of mortality (van der Zee et al, 2008).
In this study, we report the results of a model-based economic
evaluation based on evidence from a systematic review of the
literature that we carried out as part of a wider project to identify
the most appropriate testing strategies for vulval cancer. The
relative cost-effectiveness of undertaking a range of SLN biopsy
options among women with presumed stage I or stage II vulval
cancer compared with implementing ILF for all patients is
examined.
MATERIALS AND METHODS
A systematic review assessing the effectiveness of SLN biopsy in the
diagnosis and treatment of early-stage vulval cancer has already
been conducted (Meads et al, 2013). This model-based economic
evaluation relied exclusively on secondary data from the systematic
review and takes the form of a cost-effectiveness analysis, carried
out from a health-care provider perspective (in this case the UK
NHS) in a secondary care (hospital) setting.
Model structure. A model was developed via consultation within
the research team drawing on key clinical (SS, ANR and PB are all
UK accredited gynaecological oncologists and regularly practice
these procedures) and modelling expertise, using a decision tree in
TreeAge Pro 2001 software (TreeAge Software Inc., Williamstown,
MA, USA). It was felt that this approach would be most
appropriate for the evaluation rather than use a Markov model
due to the short-time horizon and there being no examples of the
same event happening to the same patient (such as a single patient
experiencing multiple groin recurrences over the 2-year time
horizon) many times in the model structure. This choice of model
structure is in line with published guidance, for example, Barton
et al (2004); Brennan et al (2006).
Women enter the model having been identified, via prior
histopathology of the primary lesion, as having presumed T1
(not T1a) or T2 FIGO stage unifocal vulval cancer. Only women
with squamous cell carcinomas were considered; all other
histological types were excluded due to their rarity and lack of
adequate data for accurate modelling.
Seven different pathways are compared that describe alternative
approaches to the SLN biopsy and the treatment of vulval cancer
(referred to using square brackets in the text). The first pathway is
the comparison arm (IFL without SLN biopsy), and is used to show
how this more morbid treatment compares with different SLN
biopsy options. In the case of pathways 2–7, SLN biopsy is
performed using either blue dye, 99mTc, or both, in order to
identify the SLN. This is followed by histopathology, which is a
combination of haematoxylin and eosin (H&E) staining and
ultrastaging in order to test for the presence of metastasis, where
ultrastaging can be considered to be representative of more
sensitive techniques such as immunohistochemistry and additional
sections. The impact of administering H&E as the routine
histopathological examination alone is also examined. For women
with metastasis detected by SLN biopsy an IFL is subsequently
performed with radiotherapy also given where necessary
(which may be necessary when more than one intranodal
metastasis and/or extracapsular spread is detected (van der Zee
et al, 2008)). Following an IFL, women are clinically monitored
every 3 months for 2 years for evidence of recurrence. If women
only receive SLN biopsy, then under these circumstances they are
clinically monitored every 2 months for 2 years, which is the
protocol for the UK. The seven patient treatment pathways
are defined as shown in Table 1.
These treatment pathways are summarised in Figure 1 and the
decision tree is shown in Figure 2. Further more detailed decision
trees are given in the Appendices.
Clinical assumptions and parameterisation. The parameterisa-
tion of the model used in this economic evaluation was undertaken
using the findings of a systematic review (Meads et al, 2013). In all
cases where the results from multiple studies could be pooled to
provide single-parameter values, these were always utilised.
However, in cases where this was not possible, the results from
Table 1. Treatment pathways used in the decision model
No. Treatment pathway Description
1 IFL IFL for all patients, with no SLN biopsy.
2 Blue dyeþH&E Blue dye is injected around the tumour intraoperatively to identify the SLN. This is followed by histopathology
consisting of H&E staining of the SLN in order to identify the presence of metastasis.
3 Blue dyeþultrastaging As for 2 but with ultrastaging of SLNs testing negative on routine H&E.
4 99mTcþH&E 99mTc (technetium-99m-labelled nanocolloid) is injected around the tumour preoperatively, and then pre-op
imaging is performed to confirm tracer-uptake in one or more SLNs. A probe is then used to detect the radioactive
signal at surgery to identify the SLN. This is followed by histopathology consisting of H&E staining of the SLN to
identify the presence of metastasis.
5 99mTcþ ultrastaging As for 4 but with ultrastaging of SLNs testing negative on routine H&E.
6 Blue dyeþ99mTcþH&E Both blue dye and 99mTc test are used to identify the SLN. Followed by H&E staining to identify the presence of
metastasis.
7 Blue dyeþ99mTcþ ultrastaging As for 6 but with ultrastaging of SLNs testing negative on routine H&E.
Abbreviations: H&E¼haematoxylin and eosin; IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node. Note: ultrastaging here can be considered to be representative of more
sensitive techniques such as immunohistochemistry.
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larger more recent studies that were identified in the systematic
review were preferred. The detection rates for the sentinel lymph
node for the different types of SLN biopsy considered in this study
are shown in Table 2. The application of the remaining parameters
in the model are described in the appendices, while the
assumptions that are required in order to develop a workable
model structure and enable the analysis to be carried out
are described in Table 3. These are broadly categorised as
assumptions related to the general pathway, recurrence and
further modelling.
All patients receive IFL with the
possibility of RT as well
For patients that have a detected SLN node, this is subject to histopathology to
detect the presence of metastasis. for patients without a detected SLN, these
are given an IFL during the same procedure and then follow the IFL pathway
Patients that test positive for the presence
of metastasis follow the IFL pathway, but
with increased monitoring (every 2
months)
Patients monitored every 3 months
Patients may experience either local
or groin recurrence. In response, they
receive either radiotherapy or
chemotherapy as appropriate (see
assumptions in the appendices)
Patients may survive or may die during next 2 years from recurrence or from un-related reason causes
Patients may experience either a local or groin recurrence. And are subsequently given either
IFL and/or radiotherapy or chemotherapy as appropriate (see assumptions in the appendices)
Patients that test true or false negative for
the presence of metastasis are not given an
IFL but instead are monitored every 2
months
Patients with vulvar cancer presumed stage 1 or stage 2
Decision: patients can receive either IFL or SLN biopsy and histopathology (see treatment pathways)
All patients receive a SLN biopsy
May experience short- / long-term morbidity
Figure 1. Summary of the decision pathway used in the economic model.
Vulvar cancer
patients with
presumed stage I
or stage II disease
Blue dye + H&E
SLN detected
IFL
SLN not detected
- follow IFL
pathway
No lymph-based
metastasis present
False positive
True negative
False negative
Lymph-based
metastasis present
True positive -
follow IFL pathway
Blue dye + ultrastaging
99mTc + H&E
99mTc + blue dye + H&E
99mTc + blue dye + ultrastaging
99mTc + ultrastaging
Figure 2. Model structure showing each of the seven primary treatment pathways, and the subsequent treatment pathway for blue dyeþH&E.
This is repeated for each of the pathways that include either blue dye and/or 99mTc.
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Cost and resource data. All costs in the model are in UK pounds
sterling d (2010 value). Three sources of data were used to
parameterise the cost component of the economic evaluation.
NHS Reference Costs 09/10, information provided by the
Histopathology Department at Birmingham City Hospital and
data collected as part of the United Kingdom Gynaecological
Oncology Surgical Outcomes and Complications audit (UKGO-
SOC), which is a prospective web-based audit examining outcomes
of surgery in gynaecological oncology particularly focused on
complications. In all cases, patients only require a maximum of one
unit of each cost depending on their treatment pathway, with the
itemised costs shown in Table 4.
Costs are given for blue dye and 99mTc when administered
separately, however, no cost was available for the two procedures
combined, and therefore it is assumed that the cost for both blue
dye and 99mTc is 10% greater than 99mTc alone (the more
expensive of the two). The impact of this assumption on model
results is examined through sensitivity analysis.
Outcomes. This economic evaluation focuses on how the different
treatment scenarios impact on the mortality and morbidity of the
patients and the costs of the different treatments. Therefore, the
economic analysis is based on the following outcomes:
1. Case of death avoided for 2 years
2. Case of survival free of morbidity for 2 years
3. Case of survival free of long-term morbidity for 2 years.
The definitions of short-term and long-term morbidity in this
study are the same as those proposed by van der Zee et al (2008)
for complications, in which short-term morbidity is defined as the
occurrence of wound breakdown or wound infection (requiring
antibiotics); and long-term morbidity is defined as lymphedema
present over two consecutive visits 41 year after primary therapy
or recurrent erysipelas (41 episode of erysipelas requiring
antibiotics).
For each of these outcomes, IFL is the reference scenario. There
are no studies that have shown a difference in the QoL estimates
for women that receive the different options considered in this
analysis. Therefore, the option of using the QALY as an outcome
measure was not available in this study.
The results are presented using the incremental cost-effective-
ness ratio (ICER), which is defined as the difference in costs
between two options divided by the difference in their effects
(which in this case are the outcome measures described above)
(Gray et al, 2011).
Analysis. The model estimates the mean costs associated with
each of the treatment strategies and assumes that all women
entering the model are aged 65 years, which is informed by the
findings of the systematic review. The time horizon of the model is
2 years, which was chosen as any groin recurrences that might
appear as a result of a false-negative SLN biopsy would be expected
to be detected within this time frame (van der Zee et al, 2008).
Owing to this short-time horizon with the majority of costs and
events occurring in the first year, no discounting was applied.
Sensitivity analysis. Probabilistic and one-way sensitivity analyses
were carried out in order to examine the robustness of the model
results to uncertainties in the model parameters and the
assumptions made. The one-way sensitivity analysis undertaken
is described in Table 5:
RESULTS
Outcomes. For overall survival for 2 years, (IFL) was the most
effective strategy. For all types of survival free of morbidity
Table 2. Detection rates for SLN biopsies used in this analysis
SLN biopsy Value Source
Blue dye 202/294 (68.7%) Pooled values taken
from Systematic review
(Meads et al, 2013)
99mTc 227/240 (94.5%)
Blue dyeþ 99mTc 1049/1074 (97.7%)
Abbreviation: SLN¼ sentinel lymph node.
Table 3. Model assumptions
General Pathway—assumptions
Patients found with a false-negative SLN biopsy (blue dye and/or 99mTc)
who subsequently develop metastasis receive both IFL and radiotherapy.
Patients are followed-up every 2 months following a negative SLN biopsy
result (and therefore do not receive IFL) and every 3 months following
an IFL.
There are no occasions in which radiotherapy might be administered to a
patient who has not previously received an IFL (apart from following a
recurrence).
Complications following a SLN biopsy (blue dye/99mTc) and then an IFL
implemented during the same procedure will be the same as those
experienced following an IFL.
Complications following all types of SLN biopsy (for example, blue dye/
99mTc) will be the same.
Recurrence—assumptions
Recurrence will only occur either in the groin or the vulva (local), distant
recurrence will not be considered. This is because any distant recurrences,
while rare are likely to occur following either a local or groin recurrence and
rarely occur without either.
An additional primary excision will be required in the case of a local
recurrence.
In the case of groin recurrence, the treatment is IFLþRT if it has not been
administered already, chemotherapy will be administered if it has.
Mortality following recurrence within the 2-year time horizon is always due to
vulval cancer, with these patients receiving palliative care as a result of their
condition. Although it is acknowledged that the findings show that the death
rate among vulval cancer patients due to vulval cancer or other causes is 50/
50 following treatment, the risk of death following a recurrence is high
enough for this assumption to be made.
Further modelling—assumptions
For the purpose of costing follow-up, all deaths from vulvar cancer and all
other causes occur at 12 months following screening.
All parameters in this model are independent of age, with the exception of
the all cause death rate. This assumption is made due to the paucity of age
specific data in this field.
Patients experience long-term complications independently of whether they
experience short-term complications. This assumption is made due to the
paucity of data in the literature describing what proportion of patients
experience both short-term and long-term complications.
Short-term and long-term morbidity have no impact on the mortality of the
patients. This assumption is made due to paucity of data, however, its impact
is investigated through sensitivity analysis.
All patients in the patient cohort are aged 65, the impact of this assumption
is investigated through sensitivity analysis by examining patients aged 55
and 75, respectively.
Abbreviations: IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
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Table 4. Breakdown of costs used in the economic analysis
Item Code Cost Reference Assumption
Radical excision MB01B d1971 UKGOSOC data 3.86 (s.e.¼ 7.75) bed days (range 1–10), administered on its
own in the case of a cancer recurrence: see assumptions in
appendix
IFL (þ radical excision) MA06Z d4129 UKGOSOC data 5.64 (s.e.¼ 9.09) bed days (range 2–11)
Radiotherapy SC22Zþ SC56Z d1728 NHS reference costs ‘3 Weeks of treatment, 5 days each week (assumption)
Chemotherapy SB12Zþ SB15Z d1270 NHS reference costs ‘Inpatient’ assume drugs from regime in band 6
ProcurementþDelivery d779þd207þd284
Monitoring of patients 503 d171 NHS reference costs Per/consultation.
Undertaken every 2 months for SLN pathways no. 2–7 (¼12
times over 2 years), every 3 months for IFL no. 1 pathway (¼8
times over 2 years)
One bed day MA06Z d312 NHS reference costs
SLN biopsy (þ radical excision)
Blue dye MA06Z d3574 NHS reference costs
(UKGOSOC data for the
bed days)
3.86 (s.e.¼ 7.75) bed days (range 1–10)
99mTc MA06ZþRA36Z d3836 NHS reference costs
(UKGOSOC data for the
bed days)
3.86 (s.e.¼ 7.75) bed days (range 1–10)
Blue dyeþ 99mTc MA06ZþRA36Z d4219 NHS reference costs
(UKGOSOC data for the
bed days)
3.86 (s.e.¼ 7.75) bed days (range 1–10)
Morbidity and mortality
Short term MA06Z d1635 NHS reference costs Mean¼5.24 (s.e.¼ 5.24 assumed) bed days (Selman, 2009)
Long term MA06Z.
502 gynaecology
d702 NHS reference costs 3 Outpatient visitsþ 1 bed day (assumed)
Vulval cancer-related
death
SD01A d436 NHS reference costs Specialist palliative care, inpatient
Histopathology
Haematoxylin and eosin d74.50 Histology department,
Birmingham City Hospital
Ultrastaging d86.75 Histology department,
Birmingham City Hospital
Table 5. Description of one-way sensitivity analysis
Parameter Baseline value Sensitivity analysis Notes
Age of the cohort 65 40–80 Impacts on overall mortality rates
Increased mortality due to
patient morbidity
None 20% Increase in overall
mortality rate for those that
experience morbidity
Cost of 99mTcþblue dye d4219 d3836–d5754 (See appendices for justification of sensitivity values)
Groin recurrence rate
following negative SLN
biopsy
6/259 (2.3%) (van der Zee
et al, 2008)
2/31 (6.5%) (Moore et al, 2008)
and a more extreme
hypothetical value of 30%
Van der Zee et al (2008) used at baseline, because it was a
much larger study. Moore study also lacked detail about uni-/
bi-focal disease
Frequency of monitoring Every 3 months for IFL, and
every 2 months for SLN
pathways (2–7)
Every 3 months for all
pathways
False-positive rate for SLN
biopsy pathways
0% 1.2% 1.2% is 95% confidence interval value calculated from a
systematic review (Meads et al, 2013). Note there was no
evidence of any values below 100% being seen in the
literature
Abbreviations: IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
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the (99mTcþ blue dyeþ ultrastaging) strategy was found to be
the most effective.
Costs. The (IFL) strategy was the cheapest, costing d9367 per
women treated for presumed stage I or stage II vulval cancer. The
most expensive was found to be the (99mTcþ blue dyeþH&E)
strategy costing d10 648 per patient (Table 6), which is due to the
extra costs incurred as a result of the additional false-negative
patients associated with this strategy having a groin node
recurrence in the future, and receiving subsequent additional
treatment and care.
Incremental analysis. In the case of the overall survival outcome
for 2 years, the (IFL) strategy dominates all other strategies as it is
both cheaper and averts the greatest mortality.
Results—survival free of morbidity for 2 years. For the outcome
of survival free of morbidity for 2 years only the strategies of (blue
dyeþ ultrastaging), (99mTcþ ultrastaging) and (99mTcþ blue
dyeþ ultrastaging) remain un-dominated by any of the alternative
treatment strategies (Table 6).
In terms of survival free of morbidity for 2 years, the most
effective strategy is the (99mTcþ blue dyeþ ultrastaging) strategy,
but this comes at a greater cost, generating an ICER of d41 200
compared with (99mTcþUltrastaging) (costs d400 more than
(99mTcþUltrastaging) with an extra 0.0097 of effectiveness),
meaning that the strategy requires an investment of d41 200 to
generate one additional case of survival free of morbidity compared
with the strategy of (99mTcþ ultrastaging). The strategy of
(99mTcþ ultrastaging) is both slightly less effective in terms of
overall survival free of morbidity and slightly less costly
than (99mTcþ blue dyeþ ultrastaging). The ICER for (99mTcþ
ultrastaging) is Bd4900 compared with (blue dyeþ ultrastaging).
The ICER for (blue dyeþ ultrastaging) is Bd2400 compared with
(IFL), that is, a financial outlay of d2400 is necessary to generate
one additional case of survival free of morbidity for 2 years
compared with the (IFL).
Results—survival free of long-term morbidity for 2 years. With
respect to survival free of long-term morbidity for 2 years, as with
survival free of morbidity the strategies of (blue dyeþ ultrastaging),
(99mTcþ ultrastaging) and (99mTcþ blue dyeþ ultrastaging)
remained un-dominated by any of the alternative treatment
strategies (Table 6).
The most effective strategy is the (99mTcþ blue dyeþ
ultrastaging) strategy, but this comes at a greater cost, generating
an ICER of d74 300, that is, the strategy requires an investment of
d74 300 to generate one additional case of survival free of long-
term morbidity compared with the strategy of (99mTcþ
ultrastaging). The strategy of (99mTcþ ultrastaging) is both
slightly less effective in terms of overall survival free of long-term
morbidity and slightly less costly than (99mTcþ blue dyeþ
ultrastaging). The ICER for (99mTcþ ultrastaging) is Bd8.900,
that is, an additional financial outlay of d8900 is necessary to
generate one case of survival free of long-term morbidity compared
with the strategy of (blue dyeþ ultrastaging).
Sensitivity analysis. The results of the sensitivity analysis are
described in the Appendices. With respect to the one-way
sensitivity analysis, only the cost of 99mTc and blue dye
implemented during the same procedure has any impact on the
conclusions drawn from the model. At baseline, it was assumed
that this procedure would cost 10% more than the cost of 99mTc
alone. However, if this was varied from being equal to the cost of
99mTc alone to costing 50% more than 99mTc alone, then this
would lead the ICER values for (99mTcþ blue dyeþ ultrastaging)
Table 6. Deterministic results for all strategies for the morbidity-related outcomes at 2 years
Pathway Cost Incremental cost Effectiveness Incremental effectiveness ICER Remarks
Survival for 2 years
IFL d9367 0.9645
Blue dyeþ ultrastaging d9775 d408 0.9427 Dominated
Blue dyeþH&E d9826 0.8782 Dominated
99mTc þultrastaging d10175 d400 0.9345 Dominated
99mTcþH&E d10245 0.8457 Dominated
99mTcþblue dyeþ ultrastaging d10576 d400 0.9335 Dominated
99mTcþblue dyeþH&E d10648 0.8418 Dominated
Survival free of morbidity for 2 years
IFL d9367 0.3512
Blue dyeþ ultrastaging d9775 d408 0.5241 0.1729 d2400
Blue dyeþH&E d9826 0.5015 Dominated
99mTc þultrastaging d10175 d400 0.6054 0.0813 d4900
99mTcþH&E d10245 0.5744 Dominated
99mTcþblue dyeþ ultrastaging d10576 d400 0.6151 0.0097 d41 200
99mTcþblue dyeþH&E d10648 0.5830 Dominated
Survival free of long-term morbidity for 2 years
IFL d9367 0.6423
Blue dyeþ ultrastaging d9775 d408 0.7534 0.1111 d3700
Blue dyeþH&E d9826 0.7105 Dominated
99mTcþultrastaging d10175 d400 0.7985 0.0451 d8900
99mTcþH&E d10245 0.7395 Dominated
99mTcþblue dyeþ ultrastaging d10576 d400 0.8039 0.0054 d74 300
99mTcþblue dyeþH&E d10648 0.7430 Dominated
Abbreviations: H&E¼ haematoxylin and eosin; ICER¼ incremental cost-effectiveness ratio; IFL¼ inguinofemoral lymphadenectomy. Incremental cost and effectiveness calculated with respect
to the preceding non-dominated strategy.
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compared with (99mTcþ ultrastaging) to range from d4700–
d195 700 and d8400–d352 600 for a case of survival free of morbidity
and survival free of long-term morbidity for 2 years, respectively.
Figure 3 shows the cost-effectiveness acceptability frontier from
the probabilistic sensitivity analysis for the outcome of survival free
of morbidity for 2 years. It can be seen that as the willingness to
pay (WTP) crosses the ICER between two non-dominated
strategies, the choice of optimal strategy changes, with a
discontinuity in the curve being seen. Up to a WTP of d3500 the
(IFL) strategy is the most cost-effective, and then from d3500 to
Bd42 000 the (99mTcþ ultrastaging) strategy is the most cost-
effective, finally for a WTP greater than Bd42 000 the (99mTcþ
blue dyeþ ultrastaging) strategy becomes the most cost-effective.
DISCUSSION
The results of the base–case analyses using the outcome of cost per
death averted for 2 years have shown that for women with
presumed stage I and stage II vulval cancer the treatment strategy
of (IFL) is both less costly and more effective than any of the other
strategies that utilise SLN biopsy. This result is not surprising given
that this procedure seeks to reduce the potential for future
recurrences at the expense of increased patient morbidity.
When considering the outcome measures of survival free of
morbidity and survival free of long-term morbidity for 2 years the
(99mTcþ ultrastaging) strategy, where ultrastaging is administered
in the case of a negative H&E test was the most cost-effective
strategy. It is also likely that the (99mTcþ ultrastagingþ blue dye)
strategy is cost-effective when compared with that of (99mTcþ
ultrastaging). However, there is some debate about this as it is
difficult to judge the acceptability thresholds of the outcome
measures used in this study (although some attempt is made
below). This is in contrast to the QALY where there are clearer
thresholds that can help to inform the acceptability of an
intervention. It can therefore be concluded that the SLN biopsy
that includes both 99mTc and ultrastaging is cost-effective in terms
of the morbidity-free outcomes for 2 years compared with IFL,
although there is some uncertainty about exactly what is the most
cost-effective SLN biopsy option.
It is noted that the strategies that included blue dye only as the
approach to the SLN biopsy, and H&E only for the histopathology
were never found to be cost-effective and were always dominated
by other strategies (other strategies being less costly and more
effective). This finding emphasises that using blue dye and
H&E for the identification of the SLN and the identification
of metastasis, respectively, are not sensitive enough to be used on
their own.
Further one-way deterministic sensitivity analysis found that the
cost of administering 99mTc and blue dye together has the
potential to have a significant impact on the results obtained from
this economic evaluation. As this is a combined technique in which
two types of SLN biopsy are implemented in the same procedure, it
is very difficult to obtain a well-informed cost for this approach.
The results here demonstrate the importance of this parameter on
the model results, but also reinforce the view that at the very least
(99mTcþ ultrastaging) is certainly a cost-effective approach to
SLN biopsy.
This economic evaluation has had the advantage of being able to
utilise the best available data in the model established in a
systematic review of the evidence (Meads et al, 2013), particularly
the sensitivity and specificity of the procedures used to identify the
SLN and any metastasis. All assumptions used in the model were
agreed by a panel of experts a priori, with key assumptions being
examined through the use of sensitivity analysis. Owing to the
scarcity of vulval cancer, many of the data points used in this
model were based on quite small samples. However, the resultant
uncertainly in these parameter values was examined through the
use of probabilistic sensitivity analysis.
The major limitation of this study is the absence of preference-
based QoL estimates that differentiate between the impact of SLN
biopsy and IFL on morbidity, making a cost-utility analysis using
the QALY as the outcome measure impossible. This is unfortunate
as there are thresholds for the acceptance of medical interventions
using the QALY in the UK (Devlin and Parkin, 2004), which are
not available for the outcome measures used in this study.
In order to provide some guidance as to the acceptability of the
strategies considered in this research, an attempt is made to link
the standard QALY thresholds to the morbidity-related outcomes
used in this study. It can be said that a patient with 2 years survival
free of morbidity will accumulate 2 QALYs within the time horizon
of the model. Strictly this should be reduced to allow for
discounting in the second year, but the difference will be small.
A patient who either does not survive 2 years or who survives with
appreciable morbidity may still accumulate some QALYs within
the 2 years. Therefore, the value of an additional positive outcome
using this measure is somewhat less than 2 QALYs. Using
the upper NICE threshold of d30 000/QALY (Devlin and
Parkin, 2004), the WTP for an additional positive outcome would
be somewhat less than d60 000, although this is subject to the
limitation that the 2 years time horizon means that no value is
being attached to any survival beyond 2 years.
Instead of the QALY, three outcome measures have been
considered in this study: overall mortality, survival free of
morbidity and survival free of long-term morbidity, all considered
over a maximum of 2 years. The inevitable difficulty with this
selection is that it is very difficult to know which primary outcome
measure is the most clinically relevant. Intuitively overall survival
would seem to be best choice, however, in this setting this outcome
provides little insight. IFL, while the cheapest strategy considered
in this analysis, is a highly morbid procedure that is most effective
at reducing the probability of a groin recurrence in the future and
hence patient mortality. The option of SLN biopsy has been
introduced into practice with the aim of reducing patient
morbidity, but at the expense of the increased possibility of
women having a false-negative diagnosis, with a resultant potential
increase in mortality. Therefore, it was inevitable that in this study
IFL has been shown to be the most effective procedure in terms of
overall survival. Perhaps the most appropriate outcome measure in
this study is survival free of morbidity, as this also incorporates all
types of morbidity and the impact of overall survival into the
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Figure 3. Cost-effectiveness acceptability frontier showing the results
of the probabilistic sensitivity analysis examining the optimal
treatment strategy across a range of willingness to pay thresholds
for the outcome of additional case of survival free of morbidity
for 2 years.
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outcome. Survival free of long-term morbidity has also been
considered because oedema, which is a long-term complication,
has been found to have a more significant impact on women
treated with IFL compared with those receiving SLN biopsy
(Oonk et al, 2009).
This analysis has highlighted the importance of obtaining
overall QoL values that describe the impact of SLN biopsy and IFL
and their related complications over time. A previous study
attempted to identify these values but did not find a difference in
overall QoL estimates between 62 women receiving either SLN
biopsy or IFL despite the observed increased morbidity among
women that underwent the IFL (Oonk et al, 2009). This may be
because the study was too small to detect a difference or because of
the type of QoL questionnaires administered, although this result
could also be explained by the extra peace of mind that the IFL
provides due to the increased possibility of a false-negative result
with SLN biopsy. Intuitively there would need to be a difference in
QoL between these two groups, as if this were not the case, IFL
with its increased effectiveness at reducing the risk of a groin
recurrence and therefore patient mortality, but with its much
higher risk of morbidity, would always be preferred. Future work
should be undertaken to examine QoL in these treatment groups
using an alternative questionnaire and larger sample size.
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APPENDIX A
Detailed decision trees showing patient pathways.
Live
Die
Local
Groin
Recurrence - Yes
Recurrence - No
Long term
morbidity - Yes
Short term
morbidity - Yes
Short term
morbidity - No
Long term
morbidity - No
Radiotherapy -
Yes
Radiotherapy -
No
IFL
Figure A1: Treatment pathway following an IFL.
Note: Patients who have a local recurrence are given a primary excision. Patients who have a groin recurrence following IFLþRT are
given chemotherapy. Patients who have a groin recurrence following an IFL only are given RT.
Live
Die
Groin
Local
Recurrence - Yes
Recurrence - No
Long term
morbidity - Yes
Short term
morbidity - Yes
Short term
morbidity - No
Long term
morbidity - No
Radiotherapy -
Yes
Radiotherapy -
No
True positive for
lymph based
metastasis - IFL
Figure A2: Treatment pathway for strategies 2–6 following a true-positive result for metastasis.
Note: Patients who have an IFL with or without RT may still go on to have either a local or groin recurrence. In the case of a local
recurrence, all patients are given a primary excision. Patients who have a groin recurrence having previously received an IFLþRT are
given chemotherapy, while for those who have only previously received an IFL are given RT.
Live
Die
Long term
morbidity - Yes
Short term
morbidity - Yes
Short term
morbidity - No
Long term
morbidity - NoRecurrence - IFL
+ RT
Long term
morbidity - Yes
Short term
morbidity - Yes
Short term
morbidity - No
Long term
morbidity - No
False negative for
lymph based
metastasis
Figure A3: Treatment pathway for strategies 2–6 following a false-negative result for metastasis.
Note: Patients who have a false-negative biopsy test result, subsequently go on to have a groin recurrence. In this case, all the patients
receive both an IFLþRT.
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Live
Die
Local recurrence -
Yes
Local recurrence -
No
Long term
morbidity - Yes
Long term
morbidity - No
Short term
morbidity - Yes
Short term
morbidity - No
True Negative
Figure A4: Treatment pathway for strategies 2–6 following a true-negative result for metastasis.
Note: Patients who have a true-negative biopsy test do not subsequently go on to have a groin recurrence. However, a local recurrence
is still possible, and under these circumstances the patients are given a primary excision.
APPENDIX B
Table A1: Model parameters
Parameter Value Reference Notes
Patients with metastasis 33.5%
(135/403)
(van der Zee et al, 2008)
Age of cohort 65 Examined in sensitivity analysis
Probabilities of recurrence
Local recurrence 34/276 (12.3%) (van der Zee et al, 2008) The possibility of local recurrence is present in all
arms of the model
Groin recurrence following IFL (no SLN biopsy) 1/32 (3.1%) (Crosbie et al, 2010) Metastasis prevalence in this study found to be 6/31.
Probability of groin recurrence given
metastasis¼ 0.1615
Groin recurrence followingnegative SLN biopsy result 6/259 (2.3%) (van der Zee et al, 2008)) Patients with unifocal vulvar disease
Groin recurrence following positive SLN biopsy and IFL 11/135 (8.1%) (Oonk et al, 2010a, b)
Groin recurrence following false-negative test 100% By definition
Death rates following recurrence and all cause
Local Recurrence 5/34 (14.75%) (van der Zee et al, 2008))
Groin Recurrence 9/11 (81.8%) (Oonk et al, 2010a, b)
All cause Age 40: 0.84%
Age 65: 1.97%
Age 80: 5.85%
Office for National Statistics (2010)
(downloaded 1/11/2011)
Calculated from: Natural Death rates. Mid-year
estimates published 30th June 2011
Probabilities of requiring radiotherapy
With an IFL strategy One (46.4%) 26/56 (Fonseca-Moutinho 2005)
After a true-positive SLN biopsy result and IFL (41.9%) 49/117 (van der Zee et al, 2008))
After a false-positive biopsy result and IFL 0% See assumptions
Following a recurrence if not previously administered 100% See assumptions
Probabilities of morbidity in the short and long term
Time frame Procedure Complication % Of patients with complications
Short term IFL (with/without SLN
biopsy)
Wound breakdown 34%
Wound cellulitis 21.3%
48.1% (22.6/47)
SLN biopsy Wound breakdown 11.7%
Wound cellulitis 4.5%
15.7% (41.4/264)
Long term IFL (with/without SLN
biopsy) and RT
Lymphedema 25.5%
Recurrent erysipelas 30.6%
48.3% (23.7/49)
IFL (with/without SLN
biopsy) no RT
Lymphedema 25.5%
Recurrent erysipelas 5.9%
29.9% (20.9/70)
SLN biopsy Lymphedema 1.9% 2.3% (6.1/264)
Abbreviations: H&E¼ haematoxylin and eosin; IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
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APPENDIX C
Calculation of histopathology test accuracy parameters
The focus of this section is in linking data describing the
prevalence of metastasis in the literature with the final outcomes
for each of the histopathology testing strategies among
patients that already have an identified SLN, namely, TP, FP, TN
and FN.
Following the identification of the SLN(s) using a SLN biopsy,
their histopathological assessment considered in this
economic evaluation is the same as that described by van der
Zee et al (2008). H&E staining of the lymph node is used,
and then if no metastasis is seen, ultrastaging with immunohis-
tochemistry is then undertaken to confirm absence/presence
of metastases.
The following calculations describe the possible outcomes
for patients that have a detected SLN that is then subject
to histopathology. As previously described, two approaches to
histopathology are considered, these being H&E þ ultrastaging
and H&E alone. These are each considered in turn:
H&E þ ultrastaging
Among patients with an identified SLN that was subject
to H&Eþ ultrastaging, van der Zee et al (2008) describe
that 6 out of 259 patients with unifocal vulval cancer and a
negative SLN following H&E and ultrastaging were subsequently
diagnosed with a groin recurrence (giving a negative predictive
value of 253/259 for H&E and ultrastaging). And therefore by
definition:
Number of false negatives (FN)¼ 6
Number of true negatives (TN)¼ 253
A systematic review (Meads et al, 2013) failed to find any
evidence of patients testing false positive for metastasis (26 studies
were considered), and so it is assumed here that FP¼ 0.
Taking the above values for FN and TN, and the assumption
that FP¼ 0, this means that the assumed prevalence of metastasis
in this study cannot fall below 2.3% (6/259).
The number of disease (metastasis) negative (DN) can be
calculated from the sum of the patients that test true negative (TN)
and false positive (FP) for metastasis (TNþ FP):
DN¼TNþ FP
As described in the table of parameters shown in Appendix B,
the proportion of patients with metastasis (p) is taken to be 0.335
(135/403). From this, the number of disease (metastasis) positive
(DP) can be calculated:
DP¼DN p/(1 p)
Taking the previously calculated values for FN and DP, the
number of true positives can now be calculated:
Number of true positives (TP)¼DP FN
Now that we have values for FN, TN, FP and TP, which are
based on values obtained from the literature, which include the
assumed prevalence of metastasis, it is straightforward to calculate
what proportion of patients will test for each of these possibilities
for H&E þ ultrastaging, with the baseline parameters shown in the
Table below.
For H&E alone
As part of the study by Oonk, et al (2010a,b) 80 out of 135
patients that were found to have metastasis were initially found
positive by H&E with the remainder being found positive through
ultrastaging. This gives the sensitivity of H&E (SensH&E) to be 59%
(80/135). However, this alone cannot be used to directly calculate
the TP and FN values for H&E, as the value for DP (used below)
incorporates information on the negative predictive value of
UltrstagingþH&E (253/259). This must also be considered here,
as patients that have a groin recurrence after ultrastagingþH&E
will certainly do the same for the less-sensitive option of H&E on
its own.
Therefore, taking the number of disease (metastasis) positive
(DP) described above for H&E þ ultrastaging, the number of true
positives and false negatives detected by H&E can be given as
follows:
Number of true positives (TPH&E)¼ SensH&E*DP
Number of false negatives (FNH&E)¼DPTPH&E
Taking the number of true negatives detected by H&E (TNH&E)
to be the same as for H&E þ ultrastaging and again assuming that
FPH&E¼ 0.
The values for FNH&E, TNH&E, FPH&E, and TPH&E allow the
proportion of patients that test for each of these possibilities for
H&E alone to be calculated, with the values used at baseline shown
in Table 4.
In all cases, the values taken from the literature, for example,
prevalence of metastasis, are varied as part of the probabilistic
sensitivity analysis in order to show their impact on the model
results.
Table A2: Parameters describing outcomes of H&E and ultrasta-
ging amongst patients with an identified sentinel lymph node
Test result H&E
H&E if negative
then ultrastaging
False negative 13.6% 1.6%
True negative 66.5% 66.5%
False positive 0.0% 0.0%
True positive 19.9% 31.9%
APPENDIX D
Probabilistic sensitivity analysis
The results described by the cost-effectiveness point estimates
do not consider any uncertainty in relation to the model input
parameters. Probabilistic sensitivity analysis (PSA) was therefore
undertaken to assess the impact of the uncertainty in the model
parameters on the results and conclusions obtained from the
model. The costs in the model are all unit costs for specific
procedures and are treated as fixed, however the number
of bed days were varied. The probabilities in the tree, these being
the proportions of patients that follow each branch were also
varied.
The standard distribution used in this analysis for the
proportions is the beta distribution. The beta distribution is
described by two parameters a and b. A beta (a, b) distribution is
able to precisely represent the uncertainty in a proportion when the
only available information is a positive cases and b, negative cases.
In all cases in this study exact numbers were available, and so these
were used to inform the parameters of each Beta distribution
directly. The bed days were described by a gamma distribution.
The method of moments approach was used to estimate the
parameters of the gamma distribution, where:
a¼ (mean^2)/(s.e.^2)
b¼ (s.e.^2)/(mean)
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Table A3: Distributions used in the probabilistic sensitivity analysis
Parameter Distribution alpha beta
Patients with metastasis* Beta 135 268
Blue dye detection rate Beta 202 92
99mTc detection rate Beta 227 13
Blue dye þ 99mTc detection rate Beta 1050 25
Negative predictive value of H&E þ ultrastaging* Beta 253 6
Sensitivity of H&E Beta 80 55
Local recurrence Beta 34 242
Groin recurrence following IFL (no SLN biopsy) Beta 1 31
Groin Recurrence following positive SLN biopsy and IFL Beta 11 124
Death following a local recurrence Beta 5 29
Death following a groin recurrence Beta 9 2
RT following IFL in the comparison arm Beta 26 30
RT with IFL following a true positive histopathology result Beta 49 68
Short-term morbidity following IFL Beta 22.6 24.4
Short-term morbidity following SLN biopsy Beta 41.4 222.6
Long-term morbidity following IFL þ RT Beta 23.7 25.3
Long-term morbidity following IFL without RT Beta 20.9 49.1
Long-term morbidity following SLN Biopsy Beta 6.1 257.9
Bed days following a primary excision/SLN biopsy Gamma 1.925 2.007
Bed days following a IFL Gamma 3.504 1.6103
Abbreviations: H&E¼ haematoxylin and eosin; IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
*It is assumed that the negative predictive value of HE þ ultrastaging is independent of the proportion of patients with metastasis.
APPENDIX E
Sensitivity analysis—results
Probabilistic sensitivity analysis
Survival at 2 years
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Figure A5: Scatterplot showing the uncertainty in costs and effectiveness within the model for each of the seven strategies for 1000 runs with
overall survival for 2 years as the outcome measure
For all values of a WTP from d0 to d100 000 for the overall survival outcome measure, the (IFL) strategy was found to be the most
cost-effective, and so the cost-effectiveness acceptability frontier for overall survival for 2 years is not shown.
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Survival free of morbidity for 2 years
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Figure A6: Scatterplot showing the uncertainty in costs and effectiveness for each of the seven strategies for 1000 runs with survival free of
morbidity as the outcome measure
See manuscript for cost-effectiveness acceptability frontier for the outcome measure of survival free of morbidity for 2 years.
Survival free of long-term morbidity for 2 Years
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Figure A7: Scatterplot showing the uncertainty in costs and effectiveness within the model for each of the 7 strategies for 1000 runs with
survival free of long-term morbidity for 2 years as the outcome measure
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Figure A8: Cost-effectiveness acceptability frontier showing the results of the sensitivity analysis examining the optimal investigative strategy
across a range of willingness to pay thresholds for the outcome of additional case of survival free of long-term morbidity
One-way sensitivity analysis
The results of the one-way sensitivity analysis are shown in the table below:
Table A4: Results of one-way sensitivity analysis
Scenario
ICER Overall survival at 2
years
ICER Survival free of morbidity
for 2 years
ICER Survival free of long-term
morbidity for 2 years
Baseline
IFL Dominates
Blue dyeþ ultrastaging d2400 d3700
99mTcþ ultrastaging d4900 d8900
99mTcþ blue dyeþ ultrastaging d41 200 d74 300
Age¼55
IFL Dominates
Blue dyeþ ultrastaging d2300 d3600
99mTcþ ultrastaging d4900 d8800
99mTcþ blue dyeþ ultrastaging d40 900 d73 800
Age¼75
IFL Dominates
Blue dyeþ ultrastaging d2400 d4200
99mTcþ ultrastaging d5100 d9000
99mTcþ blue dyeþ ultrastaging d42 600 d76 000
Increased mortality due to patient morbidity
IFL Dominates
Blue dyeþ ultrastaging d2300 d3700
99mTcþ ultrastaging d4900 d8700
99mTcþ blue dyeþ ultrastaging d40 700 d72 000
Cost of implementing 99mTc þ blue dye together
Cost of 99mTc þ blue dye¼ cost 99mTc (d3836)
IFL Dominates
Blue dyeþ ultrastaging d2400 d3700
99mTcþ blue dyeþ ultrastaging d4700 d8400
Cost of 99mTc þ blue dye¼50% more than the cost of 99mTc (d5754)
IFL Dominates
Blue dyeþ ultrastaging d2400 d3700
99mTcþ ultrastaging d4900 d8900
99mTcþ blue dyeþ ultrastaging d1 95 700 d3 52 600
Groin recurrence rate following negative SLN biopsy result for metastasis¼2/31
IFL Dominates
Blue dyeþ ultrastaging d2600 d4300
99mTcþ ultrastaging d5200 d9800
99mTcþ blue dyeþ ultrastaging d42 400 d81 300
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¼30%
IFL Dominates
Blue dyeþH&E d4800
Blue dyeþ ultrastaging d28 400
99mTcþH&E d7500
99mTcþ ultrastaging d12 000 d41 500
99mTcþ blue dyeþ ultrastaging d54 000 d2 93 400
Monitoring every 3 months for all pathways
IFL Dominates
Blue dyeþ ultrastaging d600 d900
99mTcþ ultrastaging d3500 d6300
99mTcþ blue dyeþ ultrastaging d39 800 d71 700
False positive result¼1.2% for all SLN biopsy pathways
IFL Dominates
Blue dyeþ ultrastaging d2400 d3800
99mTcþ ultrastaging d5000 d9000
99mTcþ blue dyeþ ultrastaging d41 700 d75 200
Abbreviations: H&E¼ haematoxylin and eosin; ICER¼ incremental cost-effectiveness ratio; IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
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